Thursday, June 08, 2017 8:15:52 PM
13 Pathways to DollarLand
1.) First ever Immediate Release ADF labeled opiod with ORAL AD Labeling
using the Pharmacological Approach
----------- Reformulated SequestOx™ ----------
2.) First ever generic ER ADF labeled Oxycodone ELI-201
3.) First ever generic Embeda®
4.) First ever generic Troxyca®
5.) A couple $50-100 million dollar ANDAs
6.) First ever Abuse Deterrent generic of reformulated OxyContin®
7.) File Huge Blockbuster Undisclosed NDA
8.) Lauch All four SunGen generics ($3 Billion combined markets)
9.) Buyout/Acquisition
10.)Mega Partnership !!!!
11.)Uplisting to NASDAQ exchange
12.) First ever ER opiod with out food restrictions
13.) Start PH III trials for the first ever 24 hour
1.) First ever Immediate Release ADF labeled opiod with ORAL AD Labeling
using the Pharmacological Approach
----------- Reformulated SequestOx™ ----------
2.) First ever generic ER ADF labeled Oxycodone ELI-201
3.) First ever generic Embeda®
4.) First ever generic Troxyca®
5.) A couple $50-100 million dollar ANDAs
6.) First ever Abuse Deterrent generic of reformulated OxyContin®
7.) File Huge Blockbuster Undisclosed NDA
8.) Lauch All four SunGen generics ($3 Billion combined markets)
9.) Buyout/Acquisition
10.)Mega Partnership !!!!
11.)Uplisting to NASDAQ exchange
12.) First ever ER opiod with out food restrictions
13.) Start PH III trials for the first ever 24 hour
You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
